October 31, 2017 12:33 PM EDTUpdated November 1, 10:16 AM
Pharma

As­traZeneca gets an ear­ly green light on BTK block­buster hope­ful Calquence

Brittany Meiling

Im­age: Pas­cal So­ri­ot AP Im­ages

As­traZeneca $AZN has re­ceived an ear­ly OK from reg­u­la­tors to sell its can­cer drug acal­abru­ti­nib, now un­der …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times